U.S. markets close in 4 hours 55 minutes
  • S&P 500

    4,367.19
    -75.92 (-1.71%)
     
  • Dow 30

    34,440.77
    -428.60 (-1.23%)
     
  • Nasdaq

    14,609.09
    -360.88 (-2.41%)
     
  • Russell 2000

    2,249.34
    -31.66 (-1.39%)
     
  • Crude Oil

    75.13
    -0.32 (-0.42%)
     
  • Gold

    1,734.30
    -17.70 (-1.01%)
     
  • Silver

    22.41
    -0.29 (-1.27%)
     
  • EUR/USD

    1.1675
    -0.0026 (-0.22%)
     
  • 10-Yr Bond

    1.5430
    +0.0590 (+3.98%)
     
  • GBP/USD

    1.3534
    -0.0171 (-1.25%)
     
  • USD/JPY

    111.4300
    +0.4520 (+0.41%)
     
  • BTC-USD

    41,530.90
    -1,760.05 (-4.07%)
     
  • CMC Crypto 200

    1,027.54
    -29.61 (-2.80%)
     
  • FTSE 100

    7,045.01
    -18.39 (-0.26%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Sesen Bio, Inc. (SESN) Investors to Deadline in Securities Fraud Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Hagens Berman urges Sesen Bio, Inc. (NASDAQ:SESN) investors with losses in excess of $250,000 to submit your losses now.

Class Period: Dec. 21, 2020 - Aug. 17, 2021

Lead Plaintiff Deadline: Oct. 18, 2021

Visit:www.hbsslaw.com/investor-fraud/SESN

Contact An Attorney Now:SESN@hbsslaw.com

844-916-0895

Sesen Bio, Inc. (SESN) Securities Fraud Class Action:

The complaint alleges that Defendants misrepresented clinical trial data for Sesen's lead product candidate Vicineum for the treatment of certain non-muscle invasive bladder cancer.

Specifically, Defendants concealed that: (1) the company's clinical trial for Vicineum had more than 2,000 protocol violations, including 215 classified as "major," (2) three of the company's clinical investigators were found guilty of "serious noncompliance," including backdating data, (3) the company submitted tainted data for Vicineum to the FDA, (4) the company's clinical trials showed that Vicineum leaked out into the body and caused serious side effects and increased risks for fatal liver injury.

The truth began to emerge on Aug. 13, 2021, when Sesen announced the FDA did not approve the BLA in its present form and sought additional clinical/statistical data.

Then, on Aug. 16, 2021, the company revealed it needed to conduct an additional clinical trial to provide the FDA with additional efficacy and safety data.

Finally, on Aug. 18, 2021, STAT published an article entitled "Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show." STAT cited hundreds of pages of internal documents and three people familiar with the matter reported the Vicineum clinical trial "was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose."

These events sent the price of Sesen shares sharply lower.

"We're focused on investors' losses and proving Sesen lied to them about the prospects for Vicineum," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Sesen and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sesen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SESN@hbsslaw.com.

About Hagens Berman

Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman



View source version on accesswire.com:
https://www.accesswire.com/662792/HAGENS-BERMAN-NATIONAL-TRIAL-ATTORNEYS-Alerts-Sesen-Bio-Inc-SESN-Investors-to-Deadline-in-Securities-Fraud-Class-Action-Encourages-Investors-with-Significant-Losses-to-Contact-Firms-Attorneys